Landscapes / Targets
Glucagon
A hormone that raises blood sugar and makes the body burn more energy. Drugs add it to GLP-1 for more weight loss.
9 drugs act on Glucagon, in 54 active trials · Any stage · updated 18 Nov 2026
FollowEvery change as it happens, and a Monday email
Drugs9
| Drug | How it works | Company | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
GLP-1 + glucagon |
Eli Lilly +1 · Public LLY · 1801.HK |
Approved in China | 31 Dec 2026Phase 3 trial completes | ||
| How it works | Copies two hormones | ||||
| Next date | 31 Dec 2026 · Phase 3 trial completes | ||||
| Also tested for | Obesity, Overweight and 8 more | ||||
| Open drug page | |||||
GIP + GLP-1 + glucagon |
Eli Lilly · Public LLY |
Phase 3 | Nov 2026soonPhase 3 trial completes | ||
| How it works | Copies three hormones at once | ||||
| Next date | Nov 2026 · Phase 3 trial completes | ||||
| Also tested for | Obesity, Overweight and 7 more | ||||
| Open drug page | |||||
GLP-1 + GIP + glucagon unconfirmed |
United Laboratories +1 · Public 3933.HK · NVO |
Phase 3 | 14 Jan 2027Phase 2 trial completes | ||
| How it works | Copies three hormones at once | ||||
| Next date | 14 Jan 2027 · Phase 2 trial completes | ||||
| Also tested for | Obesity, Overweight and 9 more | ||||
| Open drug page | |||||
Glucagon/GLP-1 receptor dual agonist |
Boehringer Ingelheim · Private |
Phase 3 | 17 Jan 2028Phase 3 trial completes | ||
| Next date | 17 Jan 2028 · Phase 3 trial completes | ||||
| Also tested for | Obesity, Metabolic Dysfunction Associated Steatohepatitis (MASH) and 5 more | ||||
| Open drug page | |||||
— |
Phase 3 | Apr 2028Phase 2 trial completes | |||
| Next date | Apr 2028 · Phase 2 trial completes | ||||
| Also tested for | Hypertriglyceridemia, MASLD and 2 more | ||||
| Open drug page | |||||
GLP-1 + glucagon unconfirmed |
AstraZeneca · Public AZN |
Phase 2 | 29 Jan 2027Phase 1/2 trial completes | ||
| How it works | Copies two hormones | ||||
| Next date | 29 Jan 2027 · Phase 1/2 trial completes | ||||
| Also tested for | Overweight and Obesity, Obesity/Overweight and 1 more | ||||
| Open drug page | |||||
GLP-1 + GIP + glucagon unconfirmed |
Hanmi · Public 128940.KS |
Phase 2 | Jan 2027Phase 2 trial completes | ||
| How it works | Copies three hormones at once | ||||
| Next date | Jan 2027 · Phase 2 trial completes | ||||
| Also tested for | Obese, Obesity and 1 more | ||||
| Open drug page | |||||
LY3437943not checked |
— |
Phase 2 | 14 Mar 2027Phase 2 trial completes | ||
| Next date | 14 Mar 2027 · Phase 2 trial completes | ||||
| Also tested for | Obesity | ||||
| Open drug page | |||||
Multi-receptor agonist incl. GLP-1 unconfirmed |
Phase 2 | 15 Aug 2027Phase 2 trial completes | |||
| Next date | 15 Aug 2027 · Phase 2 trial completes | ||||
| Also tested for | Obesity and Overweight | ||||
| Open drug page | |||||
No drugs match “”.
About this list
- Checked
- 8 of 9 drugs. The other 1 is marked “not checked” in the list. How we check
- Matches
- The mechanism of checked drugs, and drug names, so a drug not checked yet may be missing.
- Description
- From Wikipedia: Glucagon
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · openFDA updated 17 Nov 2026